[Form 4] Synopsys Inc Insider Trading Activity
Schedule 13G Overview: Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC (the 鈥淩eporting Persons鈥�) disclosed a collective 9.99 % beneficial ownership in Processa Pharmaceuticals Inc. (PCSA) common stock as of 20 June 2025.
Current Position (3,018,238 shares):
- 2,430,000 shares held outright by Intracoastal
- 260,000 shares issuable on exercise of Intracoastal Warrant 1
- 328,238 shares issuable on exercise of Intracoastal Warrant 2
The stake is calculated against a reference total of 30,807, (11,884,356 pre-transaction shares plus shares issued/issuable in connection with the Securities Purchase Agreement (鈥淪PA鈥�) executed on 17 June 2025).
Warrant Structure & Blockers: Both Intracoastal warrants contain a 9.99 % ownership blocker that prevents exercises which would push the Reporting Persons鈥� combined holding above that threshold. Absent these blockers, the group could control up to 10,000,000 shares.
Securities Purchase Agreement Highlights: 鈥� 1,310,000 new shares issued to Intracoastal at closing 鈥� Two warrants (Warrant 1 & Warrant 2) issued concurrently. The SPA and subsequent warrant exercises are the primary drivers of the current 9.99 % position.
Regulatory Classification: Kopin and Asher are individuals (HC, IN), while Intracoastal is a Delaware LLC (OO). The filing is made under Rule 13d-1(c).
Panoramica del Modulo 13G: Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC (i 鈥淪oggetti Dichiaranti鈥�) hanno comunicato una partecipazione beneficiaria collettiva del 9,99% nel capitale azionario ordinario di Processa Pharmaceuticals Inc. (PCSA) al 20 giugno 2025.
Posizione Attuale (3.018.238 azioni):
- 2.430.000 azioni detenute direttamente da Intracoastal
- 260.000 azioni ottenibili tramite l鈥檈sercizio del Warrant 1 di Intracoastal
- 328.238 azioni ottenibili tramite l鈥檈sercizio del Warrant 2 di Intracoastal
La quota 猫 calcolata su un totale di riferimento di 30.807.000 azioni (11.884.356 azioni pre-transazione pi霉 azioni emesse o emettibili in relazione all鈥橝ccordo di Acquisto Titoli (鈥淪PA鈥�) firmato il 17 giugno 2025).
Struttura dei Warrant e Limiti di Partecipazione: Entrambi i warrant di Intracoastal prevedono un limite di possesso del 9,99% che impedisce esercizi che porterebbero la partecipazione combinata dei Soggetti Dichiaranti oltre tale soglia. Senza questi limiti, il gruppo potrebbe controllare fino a 10.000.000 azioni.
Punti Salienti dell鈥橝ccordo di Acquisto Titoli: 鈥� 1.310.000 nuove azioni emesse a Intracoastal alla chiusura 鈥� Due warrant (Warrant 1 e Warrant 2) emessi contestualmente. Lo SPA e gli esercizi successivi dei warrant sono i principali fattori che determinano la posizione attuale del 9,99%.
Classificazione Regolamentare: Kopin e Asher sono individui (HC, IN), mentre Intracoastal 猫 una LLC del Delaware (OO). La comunicazione 猫 effettuata ai sensi della Regola 13d-1(c).
Resumen del Schedule 13G: Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC (los 鈥淚nformantes鈥�) revelaron una participaci贸n beneficiaria colectiva del 9,99% en acciones ordinarias de Processa Pharmaceuticals Inc. (PCSA) al 20 de junio de 2025.
Posici贸n Actual (3.018.238 acciones):
- 2.430.000 acciones en propiedad directa de Intracoastal
- 260.000 acciones ejercitables mediante el Warrant 1 de Intracoastal
- 328.238 acciones ejercitables mediante el Warrant 2 de Intracoastal
La participaci贸n se calcula sobre un total de referencia de 30.807.000 acciones (11.884.356 acciones previas a la transacci贸n m谩s acciones emitidas o emitibles conforme al Acuerdo de Compra de Valores (鈥淪PA鈥�) firmado el 17 de junio de 2025).
Estructura de Warrants y Restricciones: Ambos warrants de Intracoastal incluyen un l铆mite de propiedad del 9,99% que impide ejercicios que llevar铆an la participaci贸n combinada de los Informantes por encima de ese umbral. Sin estas restricciones, el grupo podr铆a controlar hasta 10.000.000 acciones.
Puntos Clave del Acuerdo de Compra de Valores: 鈥� 1.310.000 nuevas acciones emitidas a Intracoastal al cierre 鈥� Dos warrants (Warrant 1 y Warrant 2) emitidos simult谩neamente. El SPA y los ejercicios posteriores de los warrants son los principales impulsores de la posici贸n actual del 9,99%.
Clasificaci贸n Regulatoria: Kopin y Asher son individuos (HC, IN), mientras que Intracoastal es una LLC de Delaware (OO). La presentaci贸n se realiza bajo la Regla 13d-1(c).
Schedule 13G 臧滌殧: Mitchell P. Kopin, Daniel B. Asher 氚� Intracoastal Capital LLC(鈥滊炒瓿犾瀽鈥�)電� 2025雲� 6鞗� 20鞚� 旮办 Processa Pharmaceuticals Inc.(PCSA) 氤错喌欤检棎 雽�頃� 9.99%鞚� 歆戫暕鞝� 鞁れ 靻岇湢甓岇潉 瓿店皽頄堨姷雼堧嫟.
順勳灛 氤挫湢 順勴櫓 (3,018,238欤�):
- Intracoastal鞚� 歆侅爲 氤挫湢頃� 2,430,000欤�
- Intracoastal 鞗岆煱韸� 1 頄夓偓搿� 旆摑 臧�電ロ暅 260,000欤�
- Intracoastal 鞗岆煱韸� 2 頄夓偓搿� 旆摑 臧�電ロ暅 328,238欤�
歆�攵勳潃 30,807,000欤�(瓯半灅 鞝� 11,884,356欤� 氚� 2025雲� 6鞗� 17鞚� 觳搓舶霅� 歃濌秾 毵るГ 瓿勳暯靹�(鈥淪PA鈥�)鞕� 甏�霠晿鞐� 氚滍枆 霕愲姅 氚滍枆 鞓堨爼鞚� 欤检嫕 韽暔)毳� 旮办鞙茧 靷办爼霅橃棃鞀惦媹雼�.
鞗岆煱韸� 甑“ 氚� 靻岇湢 鞝滍暅: Intracoastal鞚� 霊� 鞗岆煱韸� 氇憪 靻岇湢 歆�攵勳澊 9.99%毳� 齑堦臣頃橃 鞎婋弰搿� 頃橂姅 鞝滍暅 臁绊暛鞚� 韽暔霅橃柎 鞛堨柎, 氤搓碃鞛愲摛鞚� 齑� 氤挫湢 歆�攵勳澊 鞚� 頃滊弰毳� 雱橃 鞎婋弰搿� 頄夓偓 鞝滍暅鞚� 鞛堨姷雼堧嫟. 鞚� 鞝滍暅鞚� 鞐嗢溂氅� 攴鸽９鞚� 斓滊寑 10,000,000欤�旯岇 韱奠牅頃� 靾� 鞛堨姷雼堧嫟.
歃濌秾 毵るГ 瓿勳暯靹� 欤检殧 雮挫毄: 鈥� Intracoastal鞐� 1,310,000欤检潣 鞁犾＜臧� 韥措歆� 鞁� 氚滍枆霅� 鈥� 霊� 臧滌潣 鞗岆煱韸�(Warrant 1 氚� Warrant 2)臧� 霃欖嫓鞐� 氚滍枆霅�. SPA 氚� 鞚错泟 鞗岆煱韸� 頄夓偓霌れ澊 順勳灛 9.99% 歆�攵� 氤挫湢鞚� 欤检殧 鞗愳澑鞛呺媹雼�.
攴滌牅 攵勲: Kopin瓿� Asher電� 臧滌澑(HC, IN)鞚措┌, Intracoastal電� 雿鸽澕鞗柎 LLC(OO)鞛呺媹雼�. 氤� 鞁犼碃電� Rule 13d-1(c)鞐� 霐半澕 鞝滌稖霅橃棃鞀惦媹雼�.
Pr茅sentation du Schedule 13G : Mitchell P. Kopin, Daniel B. Asher et Intracoastal Capital LLC (les 芦 D茅clarants 禄) ont divulgu茅 une participation b茅n茅ficiaire collective de 9,99 % dans les actions ordinaires de Processa Pharmaceuticals Inc. (PCSA) au 20 juin 2025.
Position actuelle (3 018 238 actions) :
- 2 430 000 actions d茅tenues directement par Intracoastal
- 260 000 actions pouvant 锚tre obtenues par l鈥檈xercice du Warrant 1 d鈥橧ntracoastal
- 328 238 actions pouvant 锚tre obtenues par l鈥檈xercice du Warrant 2 d鈥橧ntracoastal
La participation est calcul茅e sur un total de r茅f茅rence de 30 807 000 actions (11 884 356 actions avant la transaction, plus les actions 茅mises ou 脿 茅mettre dans le cadre de l鈥橝ccord d鈥橝chat de Titres (芦 SPA 禄) sign茅 le 17 juin 2025).
Structure des Warrants et limites de d茅tention : Les deux warrants d鈥橧ntracoastal comportent une clause limitant la d茅tention 脿 9,99 %, emp锚chant ainsi tout exercice qui ferait d茅passer ce seuil aux D茅clarants. Sans ces limites, le groupe pourrait contr么ler jusqu鈥櫭� 10 000 000 actions.
Points cl茅s de l鈥橝ccord d鈥橝chat de Titres : 鈥� 1 310 000 nouvelles actions 茅mises 脿 Intracoastal 脿 la cl么ture 鈥� Deux warrants (Warrant 1 et Warrant 2) 茅mis simultan茅ment. Le SPA et les exercices ult茅rieurs des warrants sont les principaux facteurs expliquant la position actuelle de 9,99 %.
Classification r茅glementaire : Kopin et Asher sont des personnes physiques (HC, IN), tandis qu鈥橧ntracoastal est une LLC du Delaware (OO). Le d茅p么t est effectu茅 conform茅ment 脿 la r猫gle 13d-1(c).
脺berblick Schedule 13G: Mitchell P. Kopin, Daniel B. Asher und Intracoastal Capital LLC (die 鈥濵elder鈥�) meldeten zum 20. Juni 2025 eine kollektive 9,99 % wirtschaftliche Beteiligung an den Stammaktien von Processa Pharmaceuticals Inc. (PCSA).
Aktuelle Position (3.018.238 Aktien):
- 2.430.000 Aktien direkt im Besitz von Intracoastal
- 260.000 Aktien, die durch Aus眉bung von Intracoastal Warrant 1 erworben werden k枚nnen
- 328.238 Aktien, die durch Aus眉bung von Intracoastal Warrant 2 erworben werden k枚nnen
Der Anteil wird auf Basis eines Referenzgesamtbestands von 30.807.000 Aktien berechnet (11.884.356 Aktien vor der Transaktion zuz眉glich der im Rahmen des am 17. Juni 2025 abgeschlossenen Wertpapierkaufvertrags (鈥濻PA鈥�) ausgegebenen oder auszugebenden Aktien).
Warrant-Struktur & Besitzbeschr盲nkungen: Beide Intracoastal-Warrants enthalten eine Besitzbeschr盲nkung von 9,99 %, die Aus眉bungen verhindert, welche die kombinierte Beteiligung der Melder 眉ber diese Schwelle hinaus erh枚hen w眉rden. Ohne diese Beschr盲nkungen k枚nnte die Gruppe bis zu 10.000.000 Aktien kontrollieren.
Wesentliche Punkte des Wertpapierkaufvertrags: 鈥� 1.310.000 neue Aktien wurden bei Abschluss an Intracoastal ausgegeben 鈥� Zwei Warrants (Warrant 1 & Warrant 2) wurden gleichzeitig ausgegeben. Der SPA und die anschlie脽enden Warrant-Aus眉bungen sind die Hauptgr眉nde f眉r die aktuelle 9,99 %-Position.
Regulatorische Klassifizierung: Kopin und Asher sind nat眉rliche Personen (HC, IN), Intracoastal ist eine Delaware LLC (OO). Die Meldung erfolgt gem盲脽 Regel 13d-1(c).
- New strategic investors (Kopin, Asher, Intracoastal) committed capital and now own 9.99 % of PCSA, signalling confidence in the company.
- Blocker provisions limit immediate dilution and prevent any single investor from surpassing 10 % control, protecting existing shareholders.
- Potential dilution: Up to 4.67 M additional shares remain issuable under Warrant 2 once the blocker allows, which could pressure future EPS.
- Increased share count: 1.31 M shares were newly issued under the SPA, immediately expanding the outstanding share base.
Insights
TL;DR 鈥� A new 9.99 % stake shows outside investor interest; dilution risk capped by blocker.
The Schedule 13G reveals that Kopin, Asher and Intracoastal Capital now hold just under 10 % of PCSA, combining common shares and warrant-backed shares. The group purposely stays below the 10 % reporting threshold via warrant blockers, signalling an intent to avoid Section 16 insider status while still maintaining meaningful influence. Roughly 2.4 M primary shares were issued at closing, increasing the public float. An additional 588 k shares could be added if the warrants shown as currently exercisable are fully converted, and as many as 4.67 M more remain restricted by the 9.99 % cap. Investors should note that鈥攚hile cash from the SPA bolsters Processa鈥檚 balance sheet鈥攆ull warrant exercise would be dilutive. For now, however, the blocker limits effective dilution and signals disciplined ownership management. The disclosure is neutral to mildly positive: it injects fresh capital and brings in sophisticated investors without ceding control.
TL;DR 鈥� Filing is routine; ownership blocker mitigates control concerns.
The 13G positions three related parties as a coordinated group holding exactly 9.99 %鈥攁 common tactic to sidestep insider designation while preserving upside via warrants. Because voting and dispositive power are reported as shared, the trio could influence shareholder votes but are unlikely to dominate governance. The blocker clauses also lower takeover-speculation risk. No board seat or activist intent is disclosed, so the immediate governance impact is limited. Should the issuer鈥檚 share count rise further, the blocker ceiling could permit additional warrant exercises without exceeding 9.99 %, gradually expanding ownership over time. Overall governance impact: low.
Panoramica del Modulo 13G: Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC (i 鈥淪oggetti Dichiaranti鈥�) hanno comunicato una partecipazione beneficiaria collettiva del 9,99% nel capitale azionario ordinario di Processa Pharmaceuticals Inc. (PCSA) al 20 giugno 2025.
Posizione Attuale (3.018.238 azioni):
- 2.430.000 azioni detenute direttamente da Intracoastal
- 260.000 azioni ottenibili tramite l鈥檈sercizio del Warrant 1 di Intracoastal
- 328.238 azioni ottenibili tramite l鈥檈sercizio del Warrant 2 di Intracoastal
La quota 猫 calcolata su un totale di riferimento di 30.807.000 azioni (11.884.356 azioni pre-transazione pi霉 azioni emesse o emettibili in relazione all鈥橝ccordo di Acquisto Titoli (鈥淪PA鈥�) firmato il 17 giugno 2025).
Struttura dei Warrant e Limiti di Partecipazione: Entrambi i warrant di Intracoastal prevedono un limite di possesso del 9,99% che impedisce esercizi che porterebbero la partecipazione combinata dei Soggetti Dichiaranti oltre tale soglia. Senza questi limiti, il gruppo potrebbe controllare fino a 10.000.000 azioni.
Punti Salienti dell鈥橝ccordo di Acquisto Titoli: 鈥� 1.310.000 nuove azioni emesse a Intracoastal alla chiusura 鈥� Due warrant (Warrant 1 e Warrant 2) emessi contestualmente. Lo SPA e gli esercizi successivi dei warrant sono i principali fattori che determinano la posizione attuale del 9,99%.
Classificazione Regolamentare: Kopin e Asher sono individui (HC, IN), mentre Intracoastal 猫 una LLC del Delaware (OO). La comunicazione 猫 effettuata ai sensi della Regola 13d-1(c).
Resumen del Schedule 13G: Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC (los 鈥淚nformantes鈥�) revelaron una participaci贸n beneficiaria colectiva del 9,99% en acciones ordinarias de Processa Pharmaceuticals Inc. (PCSA) al 20 de junio de 2025.
Posici贸n Actual (3.018.238 acciones):
- 2.430.000 acciones en propiedad directa de Intracoastal
- 260.000 acciones ejercitables mediante el Warrant 1 de Intracoastal
- 328.238 acciones ejercitables mediante el Warrant 2 de Intracoastal
La participaci贸n se calcula sobre un total de referencia de 30.807.000 acciones (11.884.356 acciones previas a la transacci贸n m谩s acciones emitidas o emitibles conforme al Acuerdo de Compra de Valores (鈥淪PA鈥�) firmado el 17 de junio de 2025).
Estructura de Warrants y Restricciones: Ambos warrants de Intracoastal incluyen un l铆mite de propiedad del 9,99% que impide ejercicios que llevar铆an la participaci贸n combinada de los Informantes por encima de ese umbral. Sin estas restricciones, el grupo podr铆a controlar hasta 10.000.000 acciones.
Puntos Clave del Acuerdo de Compra de Valores: 鈥� 1.310.000 nuevas acciones emitidas a Intracoastal al cierre 鈥� Dos warrants (Warrant 1 y Warrant 2) emitidos simult谩neamente. El SPA y los ejercicios posteriores de los warrants son los principales impulsores de la posici贸n actual del 9,99%.
Clasificaci贸n Regulatoria: Kopin y Asher son individuos (HC, IN), mientras que Intracoastal es una LLC de Delaware (OO). La presentaci贸n se realiza bajo la Regla 13d-1(c).
Schedule 13G 臧滌殧: Mitchell P. Kopin, Daniel B. Asher 氚� Intracoastal Capital LLC(鈥滊炒瓿犾瀽鈥�)電� 2025雲� 6鞗� 20鞚� 旮办 Processa Pharmaceuticals Inc.(PCSA) 氤错喌欤检棎 雽�頃� 9.99%鞚� 歆戫暕鞝� 鞁れ 靻岇湢甓岇潉 瓿店皽頄堨姷雼堧嫟.
順勳灛 氤挫湢 順勴櫓 (3,018,238欤�):
- Intracoastal鞚� 歆侅爲 氤挫湢頃� 2,430,000欤�
- Intracoastal 鞗岆煱韸� 1 頄夓偓搿� 旆摑 臧�電ロ暅 260,000欤�
- Intracoastal 鞗岆煱韸� 2 頄夓偓搿� 旆摑 臧�電ロ暅 328,238欤�
歆�攵勳潃 30,807,000欤�(瓯半灅 鞝� 11,884,356欤� 氚� 2025雲� 6鞗� 17鞚� 觳搓舶霅� 歃濌秾 毵るГ 瓿勳暯靹�(鈥淪PA鈥�)鞕� 甏�霠晿鞐� 氚滍枆 霕愲姅 氚滍枆 鞓堨爼鞚� 欤检嫕 韽暔)毳� 旮办鞙茧 靷办爼霅橃棃鞀惦媹雼�.
鞗岆煱韸� 甑“ 氚� 靻岇湢 鞝滍暅: Intracoastal鞚� 霊� 鞗岆煱韸� 氇憪 靻岇湢 歆�攵勳澊 9.99%毳� 齑堦臣頃橃 鞎婋弰搿� 頃橂姅 鞝滍暅 臁绊暛鞚� 韽暔霅橃柎 鞛堨柎, 氤搓碃鞛愲摛鞚� 齑� 氤挫湢 歆�攵勳澊 鞚� 頃滊弰毳� 雱橃 鞎婋弰搿� 頄夓偓 鞝滍暅鞚� 鞛堨姷雼堧嫟. 鞚� 鞝滍暅鞚� 鞐嗢溂氅� 攴鸽９鞚� 斓滊寑 10,000,000欤�旯岇 韱奠牅頃� 靾� 鞛堨姷雼堧嫟.
歃濌秾 毵るГ 瓿勳暯靹� 欤检殧 雮挫毄: 鈥� Intracoastal鞐� 1,310,000欤检潣 鞁犾＜臧� 韥措歆� 鞁� 氚滍枆霅� 鈥� 霊� 臧滌潣 鞗岆煱韸�(Warrant 1 氚� Warrant 2)臧� 霃欖嫓鞐� 氚滍枆霅�. SPA 氚� 鞚错泟 鞗岆煱韸� 頄夓偓霌れ澊 順勳灛 9.99% 歆�攵� 氤挫湢鞚� 欤检殧 鞗愳澑鞛呺媹雼�.
攴滌牅 攵勲: Kopin瓿� Asher電� 臧滌澑(HC, IN)鞚措┌, Intracoastal電� 雿鸽澕鞗柎 LLC(OO)鞛呺媹雼�. 氤� 鞁犼碃電� Rule 13d-1(c)鞐� 霐半澕 鞝滌稖霅橃棃鞀惦媹雼�.
Pr茅sentation du Schedule 13G : Mitchell P. Kopin, Daniel B. Asher et Intracoastal Capital LLC (les 芦 D茅clarants 禄) ont divulgu茅 une participation b茅n茅ficiaire collective de 9,99 % dans les actions ordinaires de Processa Pharmaceuticals Inc. (PCSA) au 20 juin 2025.
Position actuelle (3 018 238 actions) :
- 2 430 000 actions d茅tenues directement par Intracoastal
- 260 000 actions pouvant 锚tre obtenues par l鈥檈xercice du Warrant 1 d鈥橧ntracoastal
- 328 238 actions pouvant 锚tre obtenues par l鈥檈xercice du Warrant 2 d鈥橧ntracoastal
La participation est calcul茅e sur un total de r茅f茅rence de 30 807 000 actions (11 884 356 actions avant la transaction, plus les actions 茅mises ou 脿 茅mettre dans le cadre de l鈥橝ccord d鈥橝chat de Titres (芦 SPA 禄) sign茅 le 17 juin 2025).
Structure des Warrants et limites de d茅tention : Les deux warrants d鈥橧ntracoastal comportent une clause limitant la d茅tention 脿 9,99 %, emp锚chant ainsi tout exercice qui ferait d茅passer ce seuil aux D茅clarants. Sans ces limites, le groupe pourrait contr么ler jusqu鈥櫭� 10 000 000 actions.
Points cl茅s de l鈥橝ccord d鈥橝chat de Titres : 鈥� 1 310 000 nouvelles actions 茅mises 脿 Intracoastal 脿 la cl么ture 鈥� Deux warrants (Warrant 1 et Warrant 2) 茅mis simultan茅ment. Le SPA et les exercices ult茅rieurs des warrants sont les principaux facteurs expliquant la position actuelle de 9,99 %.
Classification r茅glementaire : Kopin et Asher sont des personnes physiques (HC, IN), tandis qu鈥橧ntracoastal est une LLC du Delaware (OO). Le d茅p么t est effectu茅 conform茅ment 脿 la r猫gle 13d-1(c).
脺berblick Schedule 13G: Mitchell P. Kopin, Daniel B. Asher und Intracoastal Capital LLC (die 鈥濵elder鈥�) meldeten zum 20. Juni 2025 eine kollektive 9,99 % wirtschaftliche Beteiligung an den Stammaktien von Processa Pharmaceuticals Inc. (PCSA).
Aktuelle Position (3.018.238 Aktien):
- 2.430.000 Aktien direkt im Besitz von Intracoastal
- 260.000 Aktien, die durch Aus眉bung von Intracoastal Warrant 1 erworben werden k枚nnen
- 328.238 Aktien, die durch Aus眉bung von Intracoastal Warrant 2 erworben werden k枚nnen
Der Anteil wird auf Basis eines Referenzgesamtbestands von 30.807.000 Aktien berechnet (11.884.356 Aktien vor der Transaktion zuz眉glich der im Rahmen des am 17. Juni 2025 abgeschlossenen Wertpapierkaufvertrags (鈥濻PA鈥�) ausgegebenen oder auszugebenden Aktien).
Warrant-Struktur & Besitzbeschr盲nkungen: Beide Intracoastal-Warrants enthalten eine Besitzbeschr盲nkung von 9,99 %, die Aus眉bungen verhindert, welche die kombinierte Beteiligung der Melder 眉ber diese Schwelle hinaus erh枚hen w眉rden. Ohne diese Beschr盲nkungen k枚nnte die Gruppe bis zu 10.000.000 Aktien kontrollieren.
Wesentliche Punkte des Wertpapierkaufvertrags: 鈥� 1.310.000 neue Aktien wurden bei Abschluss an Intracoastal ausgegeben 鈥� Zwei Warrants (Warrant 1 & Warrant 2) wurden gleichzeitig ausgegeben. Der SPA und die anschlie脽enden Warrant-Aus眉bungen sind die Hauptgr眉nde f眉r die aktuelle 9,99 %-Position.
Regulatorische Klassifizierung: Kopin und Asher sind nat眉rliche Personen (HC, IN), Intracoastal ist eine Delaware LLC (OO). Die Meldung erfolgt gem盲脽 Regel 13d-1(c).
FAQ
How many PCSA shares do Kopin, Asher and Intracoastal Capital currently own?
What percentage of Processa Pharmaceuticals (PCSA) does the reporting group control?
How are the 3,018,238 shares broken down between common shares and warrants?
What is the purpose of the 9.99 % blocker in the warrants?
Could the group鈥檚 stake in PCSA rise above 9.99 % in the future?
When was the Securities Purchase Agreement executed?
